Femasys Welcomes Congresswoman Lucy McBath
Femasys, Inc. (Nasdaq: FEMY), a leading biomedical company committed to addressing the significant unmet needs of women worldwide, recently hosted Congresswoman Lucy McBath for an in-depth tour of its headquarters. This event highlighted Femasys’ innovative therapeutic and diagnostic products aimed at improving women's health.
Emphasis on Women's Health
Kathy Lee-Sepsick, the Founder, President, and CEO of Femasys, stated, “Women’s reproductive health continues to be underfunded and underserved in many areas. Engaging with leaders like Congresswoman McBath is crucial as we develop our advanced solutions that strive to make reproductive health options more accessible and effective.”
Dedication to Innovation
The company boasts a portfolio of four FDA-cleared products: FemaSeed, an innovative intratubal insemination solution; FemVue, a device for generating contrast in fallopian tube assessments; FemCath, a selective delivery catheter; and FemCerv, an endocervical tissue sampler. These products have also received regulatory approval in various international markets, underscoring Femasys’ commitment to enhancing women’s health globally.
Transforming Reproductive Health Solutions
FemBloc, currently in late-stage clinical development, is a non-surgical, permanent birth control option that aims to revolutionize reproductive health by providing a safer and more cost-effective alternative to traditional surgical methods. This innovation reflects Femasys’ mission to empower women with more choices in their reproductive journeys.
Supporting Diagnostic Solutions
Femasys provides a variety of diagnostic solutions that complement its therapeutic offerings, improving overall effectiveness. FemVue aids in the assessment of fallopian tubes through ultrasound, while FemCath facilitates selective evaluations. FemCerv is crucial for cervical cancer diagnosis, completing Femasys’ comprehensive suite of women’s health products.
About Femasys
Femasys is a prominent biomedical company dedicated to delivering innovative health solutions for women around the globe. With a diverse range of FDA-cleared products, the company focuses on addressing critical health needs through advanced technology. Notably, FemaSeed is a groundbreaking infertility treatment that has received regulatory approvals in the U.S., Canada, and Europe, highlighting its importance in the reproductive health field.
Looking Ahead
The company is set for continued growth as it aims to expand its product range and enhance its services to better serve women's needs. Femasys is committed to building strong relationships with key stakeholders in government, healthcare, and advocacy, reinforcing its dedication to innovation and accessibility in reproductive healthcare.
Contact Information
For investor inquiries, please contact Gene Mannheimer at IR@femasys.com. For media inquiries, reach out to Kati Waldenburg at Media@femasys.com.
Frequently Asked Questions
What is Femasys known for?
Femasys is recognized for its innovative therapeutic and diagnostic solutions that focus on women's reproductive health.
What products does Femasys offer?
Femasys offers several products, including FemaSeed, FemVue, FemCath, and FemCerv, which support reproductive health and diagnostics.
What is FemBloc?
FemBloc is a non-surgical, permanent birth control method developed by Femasys that is currently in late-stage clinical development.
How does Femasys support women’s health?
Femasys addresses crucial unmet needs by providing accessible, effective, and innovative healthcare solutions for women worldwide.
Can you provide the company’s contact details?
Investors can contact Gene Mannheimer at IR@femasys.com, and media inquiries can be directed to Kati Waldenburg at Media@femasys.com.
